Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06031818 |
Recruitment Status :
Recruiting
First Posted : September 11, 2023
Last Update Posted : February 6, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The goal of this in-silico clinical trial is to learn about the usability and clinical effectiveness of an interpretable deep learning framework (VAE-MLP) using counterfactual explanations and layerwise relevance propagation for prediction of post-hepatectomy liver failure (PHLF) in patients with hepatocellular carcinoma (HCC). The main questions it aims to answer are:
- To investigate the usability of the VAE-MLP framework for explanation of the deep learning model.
- To investigate the clinical effectiveness of VAE-MLP framework for prediction of post-hepatectomy liver failure in patients with hepatocellular carcinoma.
In the usability trial the clinicians and radiologists will be shown the counterfactual explanations and layerwise relevance propagation (LRP) plots to evaluate the usability of the framework.
In the clinical trial the clinicians and radiologists will make the prediction under two different conditions: with model explanation and without model explanation with a washout period of at least 14 days to evaluate the clinical effectiveness of the explanation framework.
Condition or disease | Intervention/treatment |
---|---|
Post-hepatectomy Liver Failure Hepatocellular Carcinoma Artificial Intelligence | Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation Other: The model prediction Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation |
Post-hepatectomy liver failure (PHLF) is a severe complication after liver resection. It is important to develop an interpretable model for predicting PHLF in order to facilitate effective collaboration with clinicians for decision-making. Two-dimensional shear wave elastography (2D-SWE) is a liver stiffness measurement (LSM) technology that was proven to be useful in liver fibrosis staging. Therefore 2D-SWE shows the potential value for liver function assessment and PHLF prediction. 2D-SWE images display color-coded tissue stiffness map of liver parenchyma, with red representing a solid tissue (higher stiffness) and blue representing a soft tissue (lower stiffness). Routine analysis of 2D-SWE fails to fully utilize all information available in the images and also suffers from inter-observer variance in choosing the optimal quantification region.
Deep learning (DL) has demonstrated state-of-the-art performance on many medical imaging tasks such as classification or segmentation. However, despite significant progress in DL, the clinical translation of DL tools has so far been limited, partially due to a lack of interpretability of models, the so-called "black box" problem. Interpretability of DL systems is important for fostering clinical trust as well as timely correcting any faulty processes in the algorithms.
Here, the investigators present a novel interpretable DL framework (VAE-MLP) which incorporates counterfactual analysis for the explanation of 2D medical images and LRP for the explanation of feature attributions of both medical images and clinical variables.
The goal of this in-silico clinical trial is to learn about the usability and clinical effectiveness of an interpretable deep learning framework (VAE-MLP) using counterfactual explanations and layerwise relevance propagation for prediction of post-hepatectomy liver failure (PHLF) in patients with hepatocellular carcinoma. The main questions it aims to answer are:
- To investigate the usability of the the interpretable deep learning framework (VAE-MLP) for explanation of the deep learning model.
- To investigate the clinical effectiveness of the interpretable deep learning framework (VAE-MLP) for prediction of post-hepatectomy liver failure in patients with hepatocellular carcinoma.
In the usability trial the clinicians and radiologists will be shown the counterfactual explanations and layerwise relevance propagation plots of 6 examples. The score of the Likert scale of a designed questionnaire is used to evaluate the usability of the framework.
In the clinical trial the clinicians and radiologists will make the prediction under two different conditions: with model explanation and without model explanation with a washout period of at least 14 days. The accuracy, sensitivity and specificity is used to compare the clinical effectiveness of the explanation framework.
Study Type : | Observational |
Estimated Enrollment : | 80 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework (VAE-MILP) Using Counterfactual Explanations and Layerwise Relevance Propagation Framework for Post-Hepatectomy Liver Failure Prediction |
Actual Study Start Date : | December 10, 2023 |
Estimated Primary Completion Date : | February 28, 2024 |
Estimated Study Completion Date : | March 15, 2024 |
Group/Cohort | Intervention/treatment |
---|---|
Patients with HCC
Patients who underwent curative liver resection for HCC in the First Affiliated Hospital of Sun Yat-Sen University in China.
|
Other: The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation
The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will fill in a questionnaire to evaluate the usability of the interpretable framework. Other: The model prediction The radiologist and clinicians will be provided the model prediction results without the explanation of the model and they will be asked to give their own prediction. Other: The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation The radiologist and clinicians will be provided the model prediction results with the explanation of the model and they will be asked to give their own prediction. |
- Clinical effectiveness of the explanation framework [ Time Frame: From enrollment to the end of trial at 8 weeks ]The accuracy, sensitivity and specificity will be compared between the prediction made with and without the explanation of the DL model to determine the clinical effectiveness of the explanation framework.
- Usability of the explanation framework [ Time Frame: From enrollment to the end of trial at 8 weeks ]The score of the Likert scale of a designed questionnaire is used to evaluate the usability of the framework. Each item is given a score from 1 to 5. Higher scores mean a better outcome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients with treatment-naive and resectable HCC;
- performance status Eastern Cooperative Oncology Group (PS) score 0-1.
Exclusion Criteria:
- liver resection was not performed;
- pathological diagnosis of non-HCC;
- failure in liver stiffness measurement defined as the elastography color map was less than 75% filled or interquartile range (IQR)/median > 30%;
- immune-active chronic hepatitis indicated by an elevation of alanine aminotransferase (ALT) levels ≥ 2×upper limit of normal (ULN);
- obstructive jaundice or dilated intrahepatic bile ducts with a diameter of >3 mm;
- hypoalbuminemia, hyperbilirubinemia, or coagulopathy not related to the liver.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06031818
Contact: Xian Zhong | 86-13632460144 | x.zhong@maastrichtuniversity.nl |
China, Guangdong | |
The First Affiliated Hospital of Sun Yat-Sen University | Recruiting |
Guangzhou, Guangdong, China, 510000 | |
Contact: Xian Zhong 86-13632460144 x.zhong@maastrichtuniversity.nl |
Principal Investigator: | Philippe Lambin | Maastricht University |
Responsible Party: | Maastricht University |
ClinicalTrials.gov Identifier: | NCT06031818 |
Other Study ID Numbers: |
Interpretable DL 92059201 ( Other Grant/Funding Number: National Natural Science Foundation of China ) |
First Posted: | September 11, 2023 Key Record Dates |
Last Update Posted: | February 6, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Individual participant data (IPD) can be shared if asked |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
deep learning interpretability post-hepatectomy liver failure hepatocellular carcinoma shear wave elastography |
Carcinoma, Hepatocellular Liver Failure Hepatic Insufficiency Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |
Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases |